Immunology in clinical practice. XVII. Immunotherapy of metastatic renal cell carcinoma. Work Group Immunotherapy, Dutch Oncology
Abstract
Metastatic renal cell carcinoma has a poor prognosis. The efficacy of immunotherapy with interferon alpha (IFN-alpha) or interleukin 2 (IL-2) or their combination has been investigated extensively. The best schedule and optimum dose and combination is not known. On the basis of three prognostic factors, viz. WHO performance score, time between initial diagnosis and treatment of metastases, and number of metastatic sites, patients can be divided in prognostic groups. Patients classified in the favourable or intermediate prognostic group may survive longer after immunotherapy and therefore are candidates for such therapy. Patients who are classified in the poor prognostic group will not profit from any known systemic therapy.
Read the paper
Related studies
- Combining in silico and in vitro approaches to identification of potent inhibitor against phospholipase A2 (PLA2)
- In silico and in vitro studies: investigating the chemical composition, DFT, molecular docking, and dynamic simulation of Satureja candidissima (Munby) Briq essential oil as a potential antibacterial agent
- Quercetin combined with ciprofloxacin and gentamicin inhibits biofilm formation and virulence in Staphylococcus aureus
- In silico study of the mechanism of action, pharmacokinetic and toxicological properties of some N-methylanthranilates and their analogs
- Anticonvulsant Effects of Citronellal, Daidzin, and Phytol, Possibly Through GABAA Receptor and Voltage-Gated Sodium Channel Interaction Pathways: In Vivo and In Silico Studies
- 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as D3R-Selective Ligands for 3D-QSAR, Docking and Molecular Dynamics Simulation Studies
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.